LONDON/SINGAPORE, June 29, 2018 – Bain Capital Private Equity, a leading global private investment firm, announced that it has signed a definitive agreement to acquire DSM Sinochem Pharmaceuticals (“DSP”), the global leader in sustainable antibiotics, next-generation statins and anti-fungals. DSP is a 50/50 Joint Venture of Royal DSM (“DSM”), a global science-based company in Nutrition, Health and Sustainable Living, and Sinochem Group (“Sinochem”), a Fortune 500 enterprise.
With roots that date back to 1869, and a long history of technical innovation, DSP develops, produces and sells intermediates, active pharmaceutical ingredients and finished dosage form pharmaceuticals. In 2017, the company generated sales of approximately €440 million. It has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the USA and Mexico, with approximately 2,000 employees.
“DSM and Sinochem have been great supporters of our vision to be the global leader in generic pharmaceuticals,” said Karl Rotthier, Chief Executive Officer of DSP. “Bain Capital is now the ideal partner to drive DSP into its next stage of global development, given its deep healthcare expertise and operational skills across its worldwide team.”
“DSP is a market leader with an international reputation for high quality products and reliability,” said Benjamin Kunstler, a Managing Director at Bain Capital Private Equity. “We believe that DSP has tremendous potential to grow organically and through acquisitions, thanks to its strong production technology, product quality, and its focus on providing pharmaceutical customers with reliable solutions to their increasingly complex supply chains. We look forward to partnering with the management team to support the company in this new stage of its development.”
The transaction is expected to be completed in the fourth quarter of 2018, subject to customary regulatory approvals and consultations.
About DSM Sinochem Pharmaceuticals
DSP is the leading company in beta-lactam antibiotics, and also provides next-generation statins and anti-fungals. DSP develops, produces and sells intermediates, active pharmaceutical ingredients and finished dosage form pharmaceuticals. Our employees worldwide work together to deliver cutting-edge generics solutions that help to keep customers ahead of the competition.
Headquartered in Singapore, the group has manufacturing sites and sales offices in China, India, the Netherlands, Spain, the USA and Mexico. DSP is a 50/50 Joint Venture of Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, and Sinochem Group, a Fortune 500 enterprise.
Bain Capital Private Equity
Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive since its founding in 1984. Bain Capital Private Equity’s global team of approximately 220 investment professionals creates value for its portfolio companies through its global platform and depth of expertise in key vertical industries including healthcare, consumer/retail, financial and business services, industrials, and technology, media and telecommunications. Bain Capital Private Equity has offices in Boston, New York, London, Munich, Mumbai, Hong Kong, Shanghai, Sydney, Tokyo, Seoul and Luxembourg and has made more than 760 primary and add-on investments to date. In addition to private equity, Bain Capital invests across asset classes including credit, public equity and venture capital, managing approximately USD 95 billion in total and leveraging the firm’s shared platform to capture opportunities in strategic areas of focus. For more information, visit www.baincapitalprivateequity.com.